Business
DBV Technologies Announces Positive Topline Results from Phase 3 VITESSE Trial of VIASKIN® Peanut Patch in Peanut Allergic Children Aged 4-7 Years
Châtillon, France, December 16, 2025 DBV Technologies Announces Positive Topline Results from Phase 3 VITESSE Trial of VIASKIN® Peanut Patch in Peanut Allergic Children Aged 4-7 Years VITESSE met its primary endpoint: the lower bound of the 95% confidence interval (CI) of the difference between treatment arms was 24.5%, exceeding the prespecified threshold of 15% 46.6% of children treated with the VIASKIN® Peanut patch met response criteria at 12 months, compared to 14.8% of children in the plac
About this update from Dbv Technologies Sa
[{"type":"image","alt":"DBV Technologies S.A.","displaySize":"","headline":null,"caption":"DBV Technologies S.A.","className":"","disableSlideshowImg":false,"size":{"original":{"width":157,"height":157,"url":"https://media.zenfs.com/en/globenewswire.com/06466da7ac8627e27b0291db4f69adde"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/nRDNubmRBJgeAgXMmddvoA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTIxMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/06466da7ac8627e27b0291db4f69adde","width":157,"height":157}},"lazy":false},{"type":"text","content":"Châtillon, France, December 16, 2025","length":36,"tagName":"p"},{"type":"text","content":"DBV Technologies Announces Positive Topline Results from Phase 3 VITESSE Trial of VIASKIN® Peanut Patch in Peanut Allergic Children Aged 4-7 Years ","length":146,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"VITESSE met its primary endpoint: the lower bound of the 95% confidence interval (CI) of the difference between treatment arms was 24.5%, exceeding the prespecified threshold of 15% ","length":181,"tagName":"p"}]},{"val":[{"type":"text","content":"46.6% of children treated with the VIASKIN® Peanut patch met response criteria at 12 months, compared to 14.8% of children in the placebo arm ","length":151,"tagName":"p"}]},{"val":[{"type":"text","content":"Safety results were consistent with the safety profile observed in the VIASKIN Peanut clinical program to date","length":110,"tagName":"p"}]},{"val":[{"type":"text","content":"BLA submission in 4-7-year-olds on track for the first half of 2026","length":67,"tagName":"p"}]},{"val":[{"type":"text","content":"Achievement of primary endpoint triggers an acceleration of the exercise period of certain warrants issued pursuant to DBV’s March 2025 financing ","length":145,"tagName":"p"}]},{"val":[{"type":"text","content":"DBV to host a conference call today at 5:00 p.m. ET to discuss the VITESSE topline results and path forward","length":107,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":761,"olType":false},{"type":"text","content":"DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT – CUSIP: 23306J309), a late-stage biopharmaceutical company, today announced that VITESSE, its pivotal Phase 3 study assessing the safety and efficacy of VIASKIN® Peanut patch for the treatment of peanut...